Iron restriction in sickle cell disease: When less is more
American Journal of Hematology · 2024-07 · 99 (7) · 1349-1359
DOI: 10.1002/ajh.27267 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 23.02.2024. Verfasst von Oswaldo L Castro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Sickle Cell Disease, Howard University, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Iron, Hemoglobin, Sickle. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL Vifor.
Abstract (Originalsprache)
Primum non nocere! Can iron deficiency, an abnormality that causes anemia, benefit people with sickle cell disease (SCD) who already have an anemia? The published literature we review appears to answer this question in the affirmative: basic science considerations, animal model experiments, and noncontrolled clinical observations all suggest a therapeutic potential of iron restriction in SCD. This is because SCD's clinical manifestations are ultimately attributable to the polymerization of hemoglobin S (HbS), a process strongly influenced by intracellular HbS concentration. Even small decrements in HbS concentration greatly reduce polymerization, and iron deficiency lowers erythrocyte hemoglobin concentration. Thus, iron deficiency could improve SCD by changing its clinical features to those of a more benign anemia (i.e., a condition with fewer or no vaso‐occlusive events). We propose that well‐designed clinical studies be implemented to definitively determine whether iron restriction is a safe and effective option in SCD. These investigations are particularly timely now that pharmacologic agents are being developed, which may directly reduce red cell hemoglobin concentrations without the need for phlebotomies to deplete total body iron.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Sickle Cell Disease, Howard University, Washington, District of Columbia, USA.
- Department of Medicine, University of Verona and AOUI Verona, Verona, Italy.
- Center for Iron Disorders, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
- Division of Hematology and Oncology, University of Alabama, Birmingham, Birmingham, Alabama, USA.
- Hematology Therapeutic Area, CSL Behring, King of Prussia, Pennsylvania, USA.
- Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
ORCID-Profile: Oswaldo L Castro, Lucia De Franceschi, Tomas Ganz, Julie Kanter, Gregory J Kato, Sant-Rayn Pasricha, Stefano Rivella, John C Wood
Förderung
- CSL Vifor
Zitieren
APA
Castro, O. L., De Franceschi, L., Ganz, T., Kanter, J., Kato, G. J., Pasricha, S. R., Rivella, S., & Wood, J. C. (2024). Iron restriction in sickle cell disease: When less is more. American Journal of Hematology, 99(7), 1349-1359. https://doi.org/10.1002/ajh.27267
Vancouver
Castro OL, De Franceschi L, Ganz T, Kanter J, Kato GJ, Pasricha SR, et al. Iron restriction in sickle cell disease: When less is more. American Journal of Hematology. 2024;99(7):1349-1359. doi:10.1002/ajh.27267
BibTeX
@article{Castro2024,
author = {Castro, Oswaldo L and De Franceschi, Lucia and Ganz, Tomas and Kanter, Julie and Kato, Gregory J and Pasricha, Sant-Rayn and Rivella, Stefano and Wood, John C},
title = {Iron restriction in sickle cell disease: When less is more},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {7},
pages = {1349--1359},
doi = {10.1002/ajh.27267}
}
EUVIMED